

BMC Infectious Diseases

Sepsis in cancer patients residing in Zimbabwe: Spectrum of bacterial and fungal aetiologies and their antimicrobial susceptibility patterns.

--Manuscript Draft--

Manuscript Number:	INFD-D-19-01177R2
Full Title:	Sepsis in cancer patients residing in Zimbabwe: Spectrum of bacterial and fungal aetiologies and their antimicrobial susceptibility patterns.
Article Type:	Research article
Section/Category:	Bacterial and fungal diseases
Funding Information:	
Abstract:	<p>Background: Cancer and sepsis comorbidity is a major public health problem in most parts of the world including Zimbabwe. The microbial aetiologies of sepsis and their antibiograms vary with time and locations. Knowledge on local microbial aetiologies of sepsis and their susceptibility patterns is critical in guiding empirical antimicrobial treatment choices.</p> <p>Methods: This was a descriptive cross-sectional study which determined the microbial aetiologies of sepsis from blood cultures of paediatric and adult cancer patients obtained between July 2016 and June 2017. The TDR-X120 blood culture system and TDR 300B auto identification machine were used for incubation of blood culture bottles and identification plus antimicrobial susceptibility testing, respectively.</p> <p>Results: A total of 142 participants were enrolled; 50 (35.2%) had a positive blood culture, with 56.0% Gram positive, 42.0% Gram-negative bacteria and 2.0% yeast isolated. Common species isolated included coagulase negative <i>Staphylococcus</i> spp. (CoNS) (22.0%), <i>E. coli</i> (16.0%), <i>K. pneumoniae</i> (14.0%), <i>E. faecalis</i> (14.0%) and <i>S. aureus</i> (8.0%). Gram-negative isolates exhibited high resistance to gentamicin (61.9%) and ceftriaxone (71.4%) which are the empiric antimicrobial agents used in our setting. Amikacin and meropenem showed 85.7% and 95.2% activity respectively against all Gram-negative isolates, whilst vancomycin and linezolid were effective against 96.2% and 100.0% of all Gram-positive isolates respectively. We isolated 10 (66.7%) extended spectrum β-lactamase (ESBL) amongst the <i>E. coli</i> and <i>K. pneumoniae</i> isolates. Ten (66.7%) of the <i>Staphylococcus</i> spp. were methicillin resistant.</p> <p>Conclusions: CoNS, <i>E. coli</i>, <i>K. pneumoniae</i>, <i>E. faecalis</i> and <i>S. aureus</i> were the major microbial drivers of sepsis amongst cancer patients in Zimbabwe. Most isolates were found to be resistant to commonly used empirical antibiotics, with isolates exhibiting high levels of ESBL and methicillin resistance carriage. A nationwide survey on microbial aetiologies of sepsis and their susceptibility patterns would assist in the guidance of effective sepsis empiric antimicrobial treatment among patients with cancer.</p>
Corresponding Author:	Frank Chinowaita Midlands State University Gweru, Midlands ZIMBABWE
Corresponding Author E-Mail:	fchinowaita@gmail.com
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	Midlands State University
Corresponding Author's Secondary Institution:	
First Author:	Frank Chinowaita
First Author Secondary Information:	
Order of Authors:	Frank Chinowaita Wendy Chaka

	Tinashe K Nyazika
	Tendai C Maboreke
	Emmanuel Tizauone
	Prichard Mapondera
	Inam Chitsike
	Andrew Z Cakana
	Rooyen Tinago Mavenyengwa
Order of Authors Secondary Information:	
Response to Reviewers:	<p>Editor Comments:</p> <p>1. We note that the order of authors has changed since original submission of the manuscript. In line with COPE guidelines, BioMed Central requires written confirmation from all authors that they agree with any proposed changes in authorship of submitted manuscripts or published articles. In such cases, we use a standardised form which we would request you and your co-authors to complete. The authorship change form can be found at the following link: https://resource-cms.springernature.com/springer-cms/rest/v1/content/7454878/data/v5</p> <p>All instructions can be found on the form, please treat the 'current authorship' section as the original authorship. Please return the form within 14 days by email to the Editorial Office with all author signatures (including those newly added/removed). Please then ensure the authors names on the title page match that on the system. Response: There could be an error; we have neither changed our authors nor the order of authorship.</p> <p>2. In the 'Abstract', please rename 'Introduction' to 'Background'. Response: We have renamed the "Introduction" to "Background" as suggested by the editor</p> <p>3. Please include a Keywords section below your abstract listing three to ten keywords representing the main content of the article. Response: We have included the Keywords as suggested</p> <p>4. Please add a "Conclusions" section after the "Discussion" section. This should state clearly the main conclusions of the research article and give a clear explanation of their importance and relevance. Response: We have added the sub-heading Conclusions</p> <p>5. Please provide a complete Declarations section before the references, including an Availability of data and materials section (we appreciate that you may have supplied some of the information in the body of the manuscript). Please note that we require all of the sections to be present (unless stated optional), as well as a "Declarations" heading. Please find instructions for completing the declarations in the submission guidelines: The Declarations sub-sections are:</p> <ul style="list-style-type: none"> - Abbreviations (if applicable) - Ethics approval and consent to participate (currently in the methods section) - Consent for publication - Availability of data and materials - Funding - Competing Interests - Authors' contributions - Acknowledgements

	<p>- Authors' Information (optional)</p> <p>If any of the sections are not relevant to your manuscript, please state "Not applicable" in the section.</p> <p>Please see here for details on the information to be included in these sections: https://bmcinfectdis.biomedcentral.com/submission-guidelines/preparing-your-manuscript/research-article</p> <p>Response: we have included the sections suggested by the editor were applicable.</p> <p>6. Please remove from the File Inventory all files you do not wish to be published alongside the manuscript. Please ensure all extra files are referred to in the text. Response: We have removed the files we do not wish included in the final publication</p> <p>7. At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files. Please ensure that all figures, tables and additional/supplementary files are cited within the text. Response: we have uploaded a clean manuscript with no track changes</p>
Additional Information:	
Question	Response
<p>Has this manuscript been submitted before to this journal or another journal in the BMC series</ a>?</p>	<p>No</p>

[Click here to view linked References](#)

1 **Sepsis in cancer patients residing in Zimbabwe: Spectrum of bacterial and**
2
3 **fungal aetiologies and their antimicrobial susceptibility patterns.**
4

5
6 Frank Chinowaita^{1,2,3}, Wendy Chaka¹, Tinashe K. Nyazika^{4,5,6}, Tendai C. Maboreke⁷,
7
8 Emmanuel Tizauone^{1,2}, Prichard Mapondera⁸, Inam Chitsike⁹, Andrew Z. Cakana⁷,
9
10 Rooyen T. Mavenyengwa¹
11

12 **Running title: Sepsis in cancer patients**
13

14
15 **Affiliation**
16

- 17
18 1. Department of Medical Microbiology, College of Health Sciences, University of
19 Zimbabwe, Zimbabwe.
20
21 2. Premier Services Medical Investments, Department of Microbiology,
22 Zimbabwe
23
24 3. Department of Pathology (Microbiology), Midlands State University,
25 Zimbabwe
26
27 4. Malawi-Liverpool-Wellcome Trust Clinical Research Programme, College of
28 Medicine, University of Malawi, Blantyre, Malawi.
29
30 5. Department of Clinical Sciences, Liverpool School of Tropical Medicine,
31 Liverpool, United Kingdom.
32
33 6. Department of Medical Microbiology, Radboud University Medical Centre,
34 Nijmegen, The Netherlands.
35
36 7. Department of Haematology, College of Health Sciences, University of
37 Zimbabwe.
38
39 8. African Society Laboratory Medicine, Addis Ababa, Ethiopia.
40
41 9. Department of Paediatrics and Child Health, College of Health Sciences,
42 University of Zimbabwe.
43
44
45
46
47
48
49
50
51
52

53 **Correspondence:** Mr Frank Chinowaita, Department of Pathology (Microbiology),
54 Midlands State University, Zimbabwe Email: fchinowaita@gmail.com
55
56
57
58
59
60
61
62
63
64
65

Abstract

Background: Cancer and sepsis comorbidity is a major public health problem in most parts of the world including Zimbabwe. The microbial aetiologies of sepsis and their antibiograms vary with time and locations. Knowledge on local microbial aetiologies of sepsis and their susceptibility patterns is critical in guiding empirical antimicrobial treatment choices.

Methods: This was a descriptive cross-sectional study which determined the microbial aetiologies of sepsis from blood cultures of paediatric and adult cancer patients obtained between July 2016 and June 2017. The TDR-X120 blood culture system and TDR 300B auto identification machine were used for incubation of blood culture bottles and identification plus antimicrobial susceptibility testing, respectively.

Results: A total of 142 participants were enrolled; 50 (35.2%) had a positive blood culture, with 56.0% Gram positive, 42.0% Gram-negative bacteria and 2.0% yeast isolated. Common species isolated included coagulase negative *Staphylococcus* spp. (CoNS) (22.0%), *E. coli* (16.0%), *K. pneumoniae* (14.0%), *E. faecalis* (14.0%) and *S. aureus* (8.0%). Gram-negative isolates exhibited high resistance to gentamicin (61.9%) and ceftriaxone (71.4%) which are the empiric antimicrobial agents used in our setting. Amikacin and meropenem showed 85.7% and 95.2% activity respectively against all Gram-negative isolates, whilst vancomycin and linezolid were effective against 96.2% and 100.0% of all Gram-positive isolates respectively. We isolated 10 (66.7%) extended spectrum β -lactamase (ESBL) amongst the *E. coli* and *K. pneumoniae* isolates. Ten (66.7%) of the *Staphylococcus* spp. were methicillin resistant.

Conclusions: CoNS, *E. coli*, *K. pneumoniae*, *E. faecalis* and *S. aureus* were the major microbial drivers of sepsis amongst cancer patients in Zimbabwe. Most

1 isolates were found to be resistant to commonly used empirical antibiotics, with
2 isolates exhibiting high levels of ESBL and methicillin resistance carriage. A
3 nationwide survey on microbial aetiologies of sepsis and their susceptibility patterns
4 would assist in the guidance of effective sepsis empiric antimicrobial treatment
5 among patients with cancer.
6
7
8
9
10

11 **Keywords**

12 Sepsis; cancer; aetiology; antimicrobial resistance; ESBL
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Background

Despite the major advances in the care of patients with cancer over the past few decades and the resultant improvement in survival, complications during the course of disease arise that are associated with significant morbidity and mortality **(1)**.

Cancer is one of the leading risk factors of developing sepsis, with cancer patients having a 10-fold relative risk compared to non-cancer patients **(2)**. In addition to being a leading cause of hospitalisation in this population, sepsis represents a common pathway of mortality among cancer patients **(3)**. The comorbidity of sepsis and cancer poses serious complications with very poor prognosis with a case fatality ratio of greater than 50% in the Americas **(4)**. Sepsis as a syndrome can result from healthcare-associated or community-acquired infection by organisms and these organisms can develop resistance to commonly prescribed antimicrobial agents **(5)**.

Without proper determination of antimicrobial susceptibility patterns of these organisms, treatment may prove to be difficult, leading to other complications like organ failure, shock and death **(6)**.

Among cancer patients with sepsis the organisms commonly isolated are bacterial or fungal pathogens, with the predominant pathogens being *Staphylococcus aureus*, *Pseudomonas* species, *Escherichia coli*, and *Candida* species **(1,7)**. Laboratory investigations in sepsis include measurement of inflammatory markers, organ function tests and identification of infectious source through blood culture plus any culture specimens to identify source of infection **(5,8)**. In Zimbabwe, sepsis diagnosis is primarily clinically based and confirmation of infection with blood cultures is not always adhered to particularly in the public health institutions.

1 According to guidelines in Zimbabwe, sepsis is empirically treated with gentamicin
2 and either benzylpenicillin or cloxacillin with ceftriaxone and chloramphenicol being
3 used as empiric antibiotics when involvement with the central nervous system is
4 suspected **(9)**. Evidence from literature demonstrates variations in aetiological
5 agents of sepsis in different geographical settings, thus microbial and antimicrobial
6 profiling should be country/region specific **(6,7,10,11)**. With the rise of antimicrobial
7 resistance among clinical isolates, it is imperative to profile the causative pathogens
8 of sepsis and their antimicrobial patterns. This could aid in reducing patient hospital
9 costs, sepsis related complications and deaths.
10
11

12 To date, the burden of sepsis in cancer patients and or their causative pathogens
13 remain sparse in Zimbabwe and Africa at large, despite the growing burden of
14 cancer. Thus, this study aimed to ascertain the microbial agents of sepsis and their
15 antimicrobial susceptibility patterns among hospitalised paediatric and adult patients
16 with cancer in Zimbabwe.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Methods

Study design and study population

Between July 2016 and June 2017, we performed a prospective descriptive cross-sectional study among hospitalised paediatric and adult haematology/oncology patients at a single centre, Parirenyatwa Group of Hospitals. It is the biggest and major referral centre for patients with cancer in Zimbabwe and is located in the capital city, Harare. The target population were paediatric patients at least 1-year of age and adult patients who had a diagnosis of cancer, presenting with signs of sepsis. The participants included had to have the following; suspected infection with at least fever ($<36^{\circ}\text{C}$ or $>38^{\circ}\text{C}$), heart rate (>90 bpm) and white cell count ($<4.0 \times 10^9$ or $>12.0 \times 10^9/\text{L}$). Clinical assessment of sepsis was done using the quick Sequential Organ Failure (qSOFA) score which includes (1) respirations >22 breaths/minute, (2) altered mentation, (3) systolic blood pressure <100 mmHg, with two or more considered 'high' risk (**12**). The qSOFA score ranges from 0 to 3, with each criterion being worth one point. When respiration rate, altered mentation, or systolic blood pressure data was not available, the corresponding criterion was set to be worth zero point. For the 48% of patients (68/142) for whom clinical data was complete, the qSOFA score (**12**), including (1) creatinine >110 $\mu\text{Mol/L}$, (2) platelets $<150 \times 10^3/\mu\text{L}$, and (3) total bilirubin >20 $\mu\text{Mol/L}$ was also calculated.

Sample collection and analysis

At least two peripheral vein blood samples were consecutively drawn aseptically for blood cultures from paediatrics (3ml each) and adult (8ml each) per participant. The TDR Resin Aerobic or TDR Resin Peds (Hunan Changsha Tiandiren Bio-Tech Co., Ltd., Changsha, China) blood culture bottles, which support growth of both aerobic

1 bacteria and mycotic yeasts, were used for sample collection from participants. The
2 collected blood culture samples were processed and cultured using standard
3 microbiology hospital protocols. Briefly, TDR Resin Aerobic or TDR Resin Peds
4 (Hunan Changsha Tiandiren Bio-Tech Co., Ltd., Changsha, China) blood culture
5 bottles, from the participants were incubated at 37°C in an automated microbial
6 detection blood culture system TDR-X120 (Hunan Changsha Tiandiren Bio-Tech
7 Co., Ltd., Changsha, China). Blood cultures read as positive by the analyser were
8 immediately retrieved, Gram stained and sub-cultured on Blood agar, MacConkey
9 agar, Chocolate agar and Sabouraud dextrose agar supplemented with
10 chloramphenicol (0.5g/l) (all Mast Group Ltd., Merseyside, UK) plates for 48-hours.
11 The blood culture system has an incubation period of up to 5-days, after which it
12 reports a blood culture specimen as negative for growth. All negative blood cultures,
13 as read by the machine, were also Gram stained and sub-cultured similarly as the
14 positive ones to confirm the negative result. We only considered a patient to be
15 infected, when at least two of the blood cultures had been positive. A single positive
16 blood culture result was interpreted as possible contamination.

39 ***Identification and antimicrobial susceptibility testing of isolates***

40 Isolates grown from culture plates were initially identified as lactose fermenting
41 coliform, non-lactose fermenting coliform, oxidase positive (non-fermenter) Gram-
42 negative rods, *Staphylococcus*, *Streptococcus* species or yeasts based on colony
43 morphology. These were further speciated by means of various biochemical tests
44 and antimicrobial susceptibility test (AST) using standard methods on the Mindray
45 TDR 300B (Hunan Changsha Tiandiren Bio-Tech Co., Ltd., Changsha, China)
46 following the manufacturer's manual. Probabilities were calculated from these results
47 using the Bifido-Matrix method to identify the most possible organism. Antimicrobial
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 susceptibility testing plates were read on the TDR 300B based on turbidity and
2 interpretations were made using breakpoints stipulated in the Clinical and Laboratory
3 Standards Institute (CLSI) 2017 guidelines **(13)**. Isolates found to be multidrug
4 resistant were tested for Extended Spectrum β -Lactamase production, methicillin
5 resistance and carbapenemase production as described in the CLSI standard **(13)**.
6
7
8
9
10
11
12 *Pseudomonas aeruginosa* ATCC® 27853, *E. coli* ATCC® 25922 and *S. aureus*
13 ATCC® 25923 strains were used for quality control (QC) during identification and
14 AST on the Mindray TDR 300B machine.
15
16
17
18
19

20 ***Statistical analysis***

21
22
23 Characteristics of the study participants were analysed using descriptive statistics
24 with results expressed as frequencies and percentages. Aetiological profiles were
25 described for the overall sample using percentages and their distribution by cancer
26 types. All data analysis was performed using Stata software v13 (StataCorp).
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Results

Demographic characteristics of the population

A total of 142 consecutive hospitalised cancer participants with clinical diagnosis of sepsis were recruited into the study, with females 76 (53.5%) and paediatric patients 86 (60.6%) being the majority. The age ranged between 1 – 85 years, with an overall median age 10 (interquartile range [IQR]: 5 – 24) years and a median in-patient hospital stay of 7 (IQR: 4 – 15) days before diagnosis of sepsis was suspected. One hundred and ten (77.5%) participants had haematological neoplasms which comprised mostly of leukaemias and lymphomas whilst 32 (22.5%) had solid tumours such as Wilms tumour, rhabdomyosarcoma and hepatocellular carcinoma. Neutropenia, one of the major sepsis risk factors, was assessed from the patients' absolute neutrophil counts. The absolute neutrophil count of patients on blood culture sample collection ranged between 20 – 102 700 cells/ μ l. Neutropenia (< 1000 cells/ μ l) as previously defined in other studies (7,14) was observed in 43 (39.1%) of the participants with haematological neoplasm and one participant with a solid tumour giving a total of 44 (31.0%) neutropenic patients. There was a strong association between having a haematological neoplasm and being neutropenic (Odds Ratio, 19.9; 95%CI 3.0 – 829.2; p -<0.001). Participants' demographic characteristics are summarised in Table 1.

Blood cultures and pathogens isolated

Of the 142 participants, fifty (35.2%) had positive blood cultures. Thirty-nine of the 110 patients with haematological malignancies had positive blood cultures with a positive isolation rate of 35.5% contributing 78% of the total number of isolates. Gram-positive bacterial pathogens were the predominant 28 (56.0%) of the

1 causative agents of sepsis in this population with coagulase negative
2 *Staphylococcus* spp. (CoNS) being the majority contributing 22.0% of the pathogens
3 isolated. *E. coli* was the second most abundant 8 (16.0%) species isolated. *Candida*
4 *albicans* was the only fungal pathogen isolated from one participant with sepsis in
5 this study. Table 2 summarises our findings.
6
7
8
9
10

11 ***Exposure to antimicrobials and antimicrobial susceptibility profiles***

12
13 One hundred and twenty-nine 129(90.8%) of our participants were exposed to at
14 least one antimicrobial agent at least 48-hours prior to blood culture collection. The
15 most commonly prescribed antibiotic was ceftriaxone 100/129 (77.5%) followed by
16 gentamicin 75/129 (58.1%) and ciprofloxacin 33 (25.6%). Twenty-seven (20.9%)
17 participants were on fluconazole therapy. At least 3 antibiotics had been
18 administered to 58.0% of the participants prior to blood culture collection.
19
20
21
22
23
24
25
26
27
28
29
30

31 After performing AST on the isolates, *Staphylococci* spp. had the highest resistance
32 to penicillin 14 (93.7%), with methicillin resistance observed in 10 (66.7%) of the
33 *Staphylococci* isolates. Based on CLSI 2017 guideline, the same results can be
34 applied to cloxacillin, augmentin and cefazolin. However, all the isolates were fully
35 susceptible to vancomycin and linezolid.
36
37
38
39
40
41
42
43

44 Among the Gram-negative bacterial isolates, antibiotics such as levofloxacin
45 (52.4%), cefepime (61.9%), ceftazidime (66.7%), piperacillin-tazobactam (71.9%),
46 amikacin (85.7%) and meropenem (95.2%) exhibited moderate to high potency
47 against all Gram-negative isolates. Ampicillin and trimethoprim-sulfamethoxazole
48 were least effective with only 4.8% of the isolates being sensitive. High level of
49 resistance was observed among *K. pneumoniae* followed by *E. coli* isolates. Among
50 *K. pneumoniae* isolates, resistance was observed in ampicillin (100%), trimethoprim-
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 sulfamethoxazole (85.7%) and third generation cephalosporins (71.4%) respectively.
2 Resistance to gentamicin, one of the first line empiric antimicrobial in our setting,
3 was 57.1% among *K. pneumoniae* isolates. Against third generation cephalosporins
4 that is ceftriaxone, an empiric antimicrobial in the local Essential Medicines List and
5 Standard Treatment Guidelines for Zimbabwe (EDLIZ), and ceftazidime, resistance
6 was observed in 71.4% of these isolates. However, isolates were fully sensitive to
7 amikacin and meropenem and moderately sensitive to cefoxitin (85.7%). *E. coli*
8 isolates were also fully susceptible to meropenem and amikacin while 75.0% of the
9 isolates were resistant to ceftriaxone, ceftazidime, gentamicin, ciprofloxacin and
10 levofloxacin (see table 4). Trimethoprim-sulfamethoxazole and ampicillin displayed
11 the least activity against *E. coli* isolates with sensitivities of 0.0% and 12.5%
12 respectively. Other isolates were few to make inferences as they were only a single
13 isolate of each species. These included *Serratia odorifera*, *Acinetobacter* species,
14 *Salmonella enteritidis*, *Enterobacter intermedium* and *Hafnia alvei*. Of note, the *S.*
15 *odorifera* was only sensitive to levofloxacin and resistant to meropenem and
16 ertapenem. Overall, the proportions of isolates resistant to empiric antimicrobial
17 agents in Zimbabwe (gentamicin and ceftriaxone) among *Enterobacteria* species
18 were 61.9% and 71.4 respectively.

19 When we investigated the *Enterococcus* species, the isolates were fully susceptible
20 to linezolid and vancomycin, while they showed high resistance to tetracycline 2
21 (20.0%) and ciprofloxacin 4 (40.0%). *E. gallinarum* was resistant to the majority of
22 drugs with the two isolates being sensitive to vancomycin and linezolid.

23 *Streptococcus* species on the other hand were all resistant (66.7%) to tetracycline,
24 ampicillin and penicillin. One *Streptococcus* species, which was identified as
25 *Streptococcus bovis*, showed resistance to vancomycin. Overall, 69.2% isolates of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Enterococcus and *Streptococcus* species were susceptible to the empiric antimicrobial agents, high dose gentamicin and penicillin.

Finally, a single isolate of *C. albicans* was the only fungal pathogen isolated from the blood cultures. It proved to be resistant to terbinafine, itraconazole and fluconazole. However, the isolate was sensitive to other antifungals such as micafungin, caspofungin, voriconazole, ketoconazole, miconazole, amphotericin B and flucytosine. Tables 3 to 5 summarises the antimicrobial susceptibility patterns of all the isolates.

Incidence of ESBL production among E. coli and K. pneumoniae isolates

Fifteen isolates of both *E. coli* and *K. pneumoniae* obtained in this study were screened for *ESBL* enzyme production and 10 (66.7%) were phenotypically confirmed to be *ESBL* producers. *E. coli* isolates were the main *ESBL* producers with 6/8 (75.0%). Four (57.1%) of the total *K. pneumoniae* isolates were also confirmed *ESBL* producers.

Discussion

1
2 Sepsis is a serious life-threatening condition that commonly manifests itself in the
3
4 cancer patients. Although there are studies that have been conducted in Africa on
5
6 cancer patients presenting with sepsis **(10,15)**, limited data regarding the profiles of
7
8 the organisms implicated and antibiotic susceptibility data exist. In this study we
9
10 report the isolation rate of bacterial and fungal pathogen from blood cultures of
11
12 cancer patients (both adults and paediatric) presenting with sepsis, as well as the
13
14 antimicrobial profiles of commonly used antibiotics in our setting. We also
15
16 demonstrate that there is a high level of resistance among pathogen causing sepsis
17
18 in our setting.
19
20
21
22
23
24

25 Patients with haematological malignancies were the majority (77.5%) and this could
26
27 be due to neutropenia secondary to chemotherapy which further exposes them to
28
29 infections. The overall proportion of the patients who were neutropenic was 31.0%
30
31 which is similar to the 30.0% reported in the USA **(7)**. Patients with haematological
32
33 malignancies showed a significantly higher proportion of neutropenia compared to
34
35 those with solid cancers, a finding similar to the Chinese and European populations
36
37 **(14,17)**.
38
39
40
41
42

43 The majority (90.8%) of the study participants were on at least one antimicrobial
44
45 agent at least 48 hours prior to blood culture collection and this was as a
46
47 consequence of their immunosuppression being caused by the cancer. However, it
48
49 was also observed that 82 (57.7%) were on a cocktail of 3 to 6 broad spectrum
50
51 antimicrobial agents contrary to the standard empirical treatment of sepsis stipulated
52
53 in the local EDLIZ **(9)**. Ceftriaxone and gentamicin were the major empirical
54
55 antibiotics used despite the recommendations that ceftriaxone should only be used
56
57
58
59
60
61
62
63
64
65

1 as second line **(9)**. Use of ceftriaxone and other antimicrobials as first line empiric
2 antimicrobial treatment could be due to limited knowledge on the implications such
3
4 as antimicrobial resistance and presumed resistance to prescribed empiric
5
6
7 treatment.
8
9

10 Our microbial pathogen isolation rate was 35.2% which is slightly higher than the
11
12 average of 20 and 30% range in most studies **(2,4,8)**. Other studies from high
13
14 income countries have, on the contrary, reported lower prevalence of sepsis among
15
16 patients with cancer including studies in Oman (5.0%) and Europe (17%) **(14,18)**.
17
18

19 Among the isolates identified, Gram-positive to Gram-negative percentage ratio was
20
21 57:43 which was comparable with the median ratio of 60:40 (range 85:15 to 26:76)
22
23 obtained in Europe **(16,19)**. This reflects a similarity in the distribution of organisms
24
25 despite geographical differences although minor difference can be encountered, like
26
27 a study in Sudan where the ratio was 83%:17% **(10)**. Most of the isolates (78.0%)
28
29 came from patients with haematological malignancies, a finding comparable to other
30
31 earlier studies **(4,14)**. The major aetiological agents of sepsis obtained from patients
32
33 with haematological cancers were CoNS, *E. coli*, *E. faecalis* and *K. pneumoniae*.
34
35

36 Similarly, other studies from Europe have reported the same organisms as the
37
38 causative agents of sepsis but with some minor variations in proportions **(14,16)**.
39
40

41 Most studies had not stratified aetiological agents with cancer type but a study in
42
43 Europe with the same stratification showed similar aetiological agents between the
44
45 two major cancer groups **(14)**.
46
47
48
49
50

51 Amikacin and meropenem were the most potent drugs against Gram-negative
52
53 isolates with more than 80.0% of the isolates being sensitive, similar to findings from
54
55 a study in the USA **(7)**. Conversely, more than 60.0% of the isolates were resistant to
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

third generation cephalosporins, in contrast with the USA and an earlier study in Zimbabwe where 80-100% were sensitive **(7,20)**. This difference could be due to the wide availability and uncontrolled use of ceftriaxone as first line treatment, as was found in this study. As also shown in this and other studies **(16,21–23)**, the increase in the emergence of ESBL producing isolates has also led to this high level of resistance to the third generation cephalosporins. Gentamicin, the most commonly used empirical aminoglycoside, also had a low activity against these Gram-negative isolates as >60.0% of the isolates were resistant. Resistance to third generation cephalosporins and gentamicin has been reported in earlier studies to be rising in low-income countries **(22,24)**. Such resistance to the empiric antimicrobial agents poses a challenge in the management of sepsis among this population as it limits treatment options hence the need to review empiric treatment options. Cefoxitin and piperacillin-tazobactam were effective against 66.7% and 71.4% of all the Gram-negative isolates. However, more than 90.0% of the isolates were resistant to trimethoprim-sulfamethoxazole and ampicillin, a finding similar to most studies worldwide **(17,20,24)**. The resistance to trimethoprim-sulfamethoxazole has been attributed to overuse of the drug as prophylaxis against *Pneumocystis jirovecii* pneumonia in HIV endemic regions such as Zimbabwe. Notably, there was one *S. odorifera* isolate that was resistant to meropenem and ertapenem. This is surprising as carbapenem resistance *Enterobacteriaceae* has not been reported before in Zimbabwe. However, the isolate was not confirmed with polymerase chain reaction for carbapenemase resistance gene carriage. Nevertheless, this could be a possible emergence of carbapenemase resistance since carbapenems are being employed routinely for management of patients in the institution under study.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Expectedly, due to their limited use locally, minocycline, chloramphenicol, linezolid and vancomycin showed to be effective against more than 80.0% of the *Staphylococcus* isolates. A moderately high activity was displayed by gentamicin, clindamycin and erythromycin. These results were partly in agreement with findings from Ghana and India **(24,25)**. Conversely, there was high rate of methicillin resistance which impliedly apply to cloxacillin, one of the EDLIZ prescribed empiric antimicrobial agent. The low activity observed in penicillin was previously reported in Ghana, India and Zimbabwe **(20,24,25)**. *Enterococcus* and *Streptococcus* species in our study were highly sensitive to fosfomicin, vancomycin and linezolid with the latter being the most effective (isolates were 100.0% sensitive) antibiotic. Contrary to findings in India where they found 50% of *Enterococcus* species to be resistant to vancomycin, all our isolates were sensitive to vancomycin **(26)**. These isolates also displayed a moderate sensitivity to gentamicin, ampicillin and penicillin. Surprisingly, one isolate of *Streptococcus bovis* was resistant to vancomycin, a finding that has not been reported before in Zimbabwe. However, vancomycin resistance amongst *Streptococcus bovis* has been reported before in some parts of the world **(27)**.

Some isolates phenotypically showed multidrug resistance capabilities. Our methicillin resistance carriage was comparable to USA isolates where MRSA was 50.0% in our current study versus 41.0% in USA while that of methicillin resistant CoNS was 75.0% versus 72.0% respectively **(7)**. In Ghana, a low proportion of MRSA (5.8%) was reported in contrast to our findings **(24)**. This high-level methicillin resistance limits the choices of antimicrobial treatment since it also implies that these isolates will also be clinically resistant to most if not all commonly used beta-lactam antibiotics. We also found a high proportion of ESBL producers among *E. coli* and *K. pneumoniae* isolates and this was in agreement with some studies around the world

1
2
3
4
5
6
7
8
9
10
(16,21,22,28). However, of note was a higher proportion of ESBL producing *E. coli*
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
(75.0%) than *K. pneumoniae* (57.1%), a different finding from most reports in other
parts of the world where ESBL production is predominantly found in *K. pneumoniae*
isolates **(21,22).**

11 **Conclusion**

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
In summary, sepsis remains a leading cause of morbidity and mortality among
patients with cancer; with the major aetiological agents being CoNS, *E. coli*, *K.*
pneumoniae, *E. faecalis* and *S. aureus*. Similar aetiological pathogens were present
in both haematological and solid cancers in the Zimbabwean population. Most of the
microbial aetiological agents of sepsis showed high levels of resistance to commonly
used antimicrobial drugs as well as to those prescribed as local empiric treatment.
Resistance to gentamicin, penicillin and third generation cephalosporins is a major
cause for concern as these are the major empirical antibiotics in resource limited
settings. Apart from vancomycin, linezolid was shown to be another better option to
be considered in the treatment of serious and non-responsive Gram-positive
infections while amikacin and meropenem can also be considered in Gram-negative
infections. The emergence of multidrug resistance mechanisms like ESBL,
carbapenemase carriage and methicillin resistance among isolates is disturbing and
this demonstrates the need for active surveillance to reduce their transmission with a
goal to mitigate mortality and morbidity among patients.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Declarations

Abbreviations

CoNS – coagulase negative *Staphylococcus*; ESBL – extended spectrum beta lactamase; MRSA – methicillin resistant *Staphylococcus aureus*; CLSI – Clinical and Laboratory Standard Institute; AST – antimicrobial susceptibility testing; ATCC – American Type Culture Collection; qSOFA – quick sequential organ failure assessment; IQR – interquartile range; EDLIZ – Essential Medicines List and Standard Treatment Guidelines for Zimbabwe

Ethics approval and consent to participate

22 This study was approved by the Joint Research Ethics Committee of the
23
24 Parirenyatwa Group of Hospitals (Harare, Zimbabwe) and the College of Health
25
26 Sciences under the University of Zimbabwe (JREC57/16), and the Medical Research
27
28 Council of Zimbabwe (MRCZ/B/1093). Informed written consent was sought from
29
30 each participant, parent or guardian.
31
32
33

Consent for publication

36 All informed written consent also included an insertion that gave consent for
37
38 publication of obtained data.
39
40

Availability of data and materials

41
42
43 Data for this study have been included within the document. For any further
44
45 information that might be required, the corresponding author is willing to provide the
46
47 information.
48
49
50

Funding

51
52 This study was self-funded
53
54
55

Competing interests

56
57 The authors declare that they have no competing interests.
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Authors' contributions

FC, RTM and WC conceived the idea. RTM, WC, AZC, IC, supervised the study.

AZC, TCM and IC helped with the clinical diagnosis of sepsis, haematological and solid cancers. FC and ET analysed the samples and collected data. TKN and PM analysed and interpreted the data. FC TKN, RTM wrote the first draft of the manuscript. FC, RTM, WC, TN and TCM revised the manuscript and approved the final version to be submitted.

Acknowledgements

The authors thank the A6 adult oncology, A4 paediatric oncology/haematology and C3 adult haematology wards staff for their valuable assistance in the identification of potential participants and blood culture specimen collection.

References

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
1. Torres VB, Azevedo LC, Silva UV, Caruso P, Torelly AP, Silva E, et al. Sepsis-associated outcomes in critically ill patients with malignancies. *Annals of the American Thoracic Society*. 2015;12(8):1185–1192.
2. Danai PA, Moss M, Mannino DM, Martin GS. The epidemiology of sepsis in patients with malignancy*. *Chest*. 2006 Jun 1; 129(6):1432–40.
3. Vincent J-L, Marshall JC, Namendys-Silva SA, François B, Martin-Loeches I, Lipman J, et al. Assessment of the worldwide burden of critical illness: The Intensive Care Over Nations (ICON) audit. *The Lancet Respiratory Medicine*. 2014 May; 2(5):380–6.
4. Williams MD, Braun LA, Cooper LM, Johnston J, Weiss RV, Qualy RL, et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. *Critical Care*. 2004;8(5):1.
5. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012. *Intensive Care Medicine*. 2013 Jan 30; 39(2):165–228.
6. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. *Virulence*. 2014 Jan 1;5(1):4–11.
7. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with haematological malignancies and solid neoplasms in hospitals in the United States. *Clinical Infectious Diseases*. 2003;36(9):1103–10.
8. Lever A, Mackenzie I. Sepsis: definition, epidemiology, and diagnosis. *British Medical Journal*. 2007 Oct 25; 335(7625):879–83.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

9. National Medicine and Therapeutics Policy Advisory Committee (Zimbabwe).

EDLIZ 2015: 7th Essential Medicines List and Standard Treatment Guidelines for

Zimbabwe [Internet]. National Medicine and Therapeutics Policy Advisory

Committee; 2015. Available from:

<https://books.google.co.zw/books?id=yFaOswEACAAJ>

10. Elseed YHAEA, Ibrahim MA, Ahmed WAM. Isolation and Identification of

Aerobic Bacterial Pathogens from Septicaemic Cancer Patients in Khartoum, Sudan.

Clinical Medicine. 2015; 1(4):122–5.

11. Awoniyi DO, Udo SJ, Oguntibeju OO. An epidemiological survey of neonatal

sepsis in a hospital in western Nigeria. African Journal of Microbiology Research.

2009 Jul 31;3(7):385–9.

12. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer

M, et al. The third international consensus definitions for sepsis and septic shock

(Sepsis-3). Journal of the American Medical Association. 2016;315(8):801–810.

13. M100-S25: Performance Standards for Antimicrobial Susceptibility Testing;

Twenty-Fifth Informational Supplement - M100S25_sample.pdf [Internet]. [cited 2017

Feb 9]. Available from: http://shop.clsi.org/site/Sample_pdf/M100S25_sample.pdf

14. Taccone FS, Artigas AA, Sprung CL, Moreno R, Sakr Y, Vincent J-L.

Characteristics and outcomes of cancer patients in European ICUs. Critical Care.

2009;13: R15.

15. El-Mahallawy H, Sidhom I, El-Din NHA, Zamzam M, El-Lamie MM. Clinical

and microbiologic determinants of serious bloodstream infections in Egyptian

pediatric cancer patients: a one-year study. International Journal of Infectious

Diseases. 2005 Jan;9(1):43–51.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
16. Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. *Journal of Infection*. 2014 Apr;68(4):321–31.
 17. Wang S-S, Lee N-Y, Hsueh P-R, Huang W-H, Tsui K-C, Lee H-C, et al. Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extended-spectrum β -lactamase-producing *Escherichia coli* or *Klebsiella pneumoniae*. *Journal of Microbiology, Immunology and Infection*. 2011 Aug 1;44(4):282–8.
 18. Prakash KP, Arora V, Geethanjali PP. Bloodstream bacterial pathogens and their antibiotic resistance pattern in Dhahira Region, Oman. *Oman Medical Journal*. 2011;26: 240–279.
 19. Mikulska M, Del Bono V, Raiola AM, Bruno B, Gualandi F, Occhini D, et al. Blood Stream Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Re-emergence of Gram-Negative Rods and Increasing Antibiotic Resistance. *Biology of Blood and Marrow Transplantation*. 2009 Jan;15(1):47–53.
 20. Musiime V, Cook A, Bakeera-Kitaka S, Vhembo T, Lutakome J, Keishanyu R, et al. Bacteremia, Causative Agents and Antimicrobial Susceptibility among HIV-1 Infected Children on Antiretroviral Therapy in Uganda and Zimbabwe: The Pediatric Infectious Disease Journal. 2013 Feb;1.
 21. Yang Q, Zhang H, Wang Y, Xu Y, Chen M, Badal RE, et al. A 10 year surveillance for antimicrobial susceptibility of *Escherichia coli* and *Klebsiella pneumoniae* in community-and hospital-associated intra-abdominal infections in China. *Journal of medical microbiology*. 2013;62(9):1343–9.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
22. Alabi AS, Frielinghaus L, Kaba H, Kösters K, Huson MAM, Kahl BC, et al. Retrospective analysis of antimicrobial resistance and bacterial spectrum of infection in Gabon, Central Africa. *BMC Infectious Diseases*. 2013;13: 455.
 23. Gudiol C, Bodro M, Simonetti A, Tubau F, González-Barca E, Císnal M, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. *Clinical Microbiology and Infection*. 2013 May 1;19(5):474–9.
 24. Acquah SE, Quaye L, Sagoe K, Ziem JB, Bromberger PI, Amponsem AA. Susceptibility of bacterial etiological agents to commonly-used antimicrobial agents in children with sepsis at the Tamale Teaching Hospital. *BMC Infectious Diseases*. 2013;13: 89.
 25. Sharma CM, Agrawal RP, Sharan H, Kumar B, Sharma D, Bhatia SS. “Neonatal Sepsis”: Bacteria & their Susceptibility Pattern towards Antibiotics in Neonatal Intensive Care Unit. *Journal of Clinical and Diagnostic Research: JCDR*. 2013 Nov;7(11):2511.
 26. Prabhash K, Medhekar A, Ghadyalpatil N, Noronha V, Biswas S, Kurkure P, et al. Blood stream infections in cancer patients: A single center experience of isolates and sensitivity pattern. *Indian Journal of Cancer*. 2010 Apr 1;47(2):184.
 27. Poyart C, Pierre C, Quesne G, Pron B, Berche P, Trieu-Cuot P. Emergence of vancomycin resistance in the genus *Streptococcus*: characterization of a vanB transferable determinant in *Streptococcus bovis*. *Antimicrobial Agents and Chemotherapy*. 1997;41(1):24–29.
 28. Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Císnal M, Sánchez-Ortega I, et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer

patients: risk factors, antibiotic therapy and outcomes. Journal of Antimicrobial
Chemotherapy. 2011 Mar 1;66(3):657–63.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1: Study population demographic characteristics

Characteristic	Total	Haematological neoplasm	Solid tumour
Female n (%)	76 (53.5)	58 (76.3)	18 (23.7)
Age median (IQR) years	-	15 (4 – 34)	6 (5 – 10)
Paediatric (oncology ward) n (%)	86	55 (64.0)	31 (36.0)
Adults (oncology ward) n (%)	1	-	1 (100.0)
Adult (haematology ward) n (%)	55	55 (100.0)	-
Hospital stay median (IQR) days	7.0 (4 – 15)	7.0 (4 – 15)	7.5 (3 – 13)
Neutropenia n (%)	44 (31.0)	42 (39.1)	1 (3.1)

n, number

Table 2: Distribution of sepsis causing pathogens in participants with cancer

Causative pathogen	Number of isolates (n)				Total (%)
	Haematological		Solid tumour		
	neoplasm		Children	adults	
	Children	Adults	Children	adults	
Gram-negative bacteria (n=21)					
<i>Escherichia coli</i>	4	2	2	-	8 (16.0)
<i>Klebsiella pneumoniae</i>	2	3	2	-	7 (14.0)
<i>Enterobacter intermedium</i>	1	-	-	-	1 (2.0)
<i>Serratia odorifera</i>	-	1	-	-	1 (2.0)
<i>Acinetobacter species</i>	1	-	-	-	1 (2.0)
<i>Pseudomonas aeruginosa</i>	1	-	-	-	1 (2.0)
<i>Salmonella enteritidis</i>	-	1	-	-	1 (2.0)
<i>Hafnia alvei</i>	-	-	1	-	1 (2.0)
Gram positive bacteria (n=28)					
CoNS	3	6	2	-	11 (22.0)
<i>Staphylococcus aureus</i>	2	1	-	1	4 (8.0)
<i>Enterococcus faecalis</i>	1	5	1	-	7 (14.0)
<i>Enterococcus gallinarum</i>	2	-	-	-	2 (4.0)
<i>Enterococcus faecium</i>	1	-	-	-	1 (2.0)
<i>Streptococcus species</i>	0	1	2	-	3 (6.0)
Fungi (n=1)					
<i>Candida albicans</i>	1	-	-	-	1 (2.0)

n, number

Table 3: Distribution of drug susceptible *Staphylococcus* species

Bacterial species isolates	N	VA	LIN	ERY	CD	TET	MINO	RIF	GM	CIP	PEN	COT
<i>S. aureus</i>	4	4	4	2	3	3	3	3	3	2	0	2
<i>CoNS</i>	11	11	11	7	7	5	9	8	6	5	1	6
Total sensitive n (%)	15(100)	15(100)	15(100)	9(60.0)	10(66.7)	8(53.3)	12(80.0)	11(73.3)	9(60.0)	7(46.7)	1(6.7)	8(53.3)

Notes: **VA**, vancomycin; **LIN**, linezolid; **ERY**, erythromycin; **CD**, clindamycin; **TET**, tetracycline; **MINO**, minocycline; **RIF**, rifampicin; **CHL**, chloramphenicol; **CIP**, ciprofloxacin; **GM**, gentamicin; **PEN**, penicillin; **COT**, trimethoprim-sulfamethoxazole; **N**, number; **(0)**, zero susceptible isolates

Table 4: Distribution of antimicrobial susceptibility patterns for gram negative isolates

Bacterial isolates	N	AMP	PTZ	CXM	CRO	CAZ	CEF	FOX	GM	AK	CIP	LEV	MEM	COT
<i>E. coli</i>	8	1	7	2	2	2	4	7	2	8	2	2	8	0
<i>K. pneumoniae</i>	7	0	4	2	2	2	4	6	3	7	3	4	7	1
<i>E. intermedium</i>	1	0	1	0	0	0	1	0	1	0	1	1	1	0
<i>S. odorifera</i>	1	0	0	0	0	0	0	0	0	0	0	1	0	0
<i>S. enteritidis</i>	1	0	1	0	1	1	1	0	0	0	1	1	1	0
<i>Acinetobacter sp.</i>	1	0	0	0	1	1	1	0	0	1	0	0	1	0
<i>P. aeruginosa</i>	1	-	1	-	0	1	1	-	1	1	1	1	1	0
<i>H. alvei</i>	1	0	1	0	0	0	1	1	1	1	1	1	1	0
Total n (%)	21	1(4.8)	15(71.4)	4(19.0)	6(28.6)	7(33.3)	13(61.9)	14(66.7)	8(38.1)	18(85.7)	9(42.9)	11(52.4)	20(95.2)	1(4.8)

Notes: AMP, ampicillin; PTZ, piperacillin-tazobactam; CRO, ceftriaxone; CAZ, ceftazidime; CXM, cefuroxime; CEF, cefepime; FOX, ceftazidime; GM, gentamicin; AK, amikacin; CIP, ciprofloxacin; LEV, levofloxacin; COT, trimethoprim-sulfamethoxazole; MEM, meropenem; N, number; (-), not tested; (0), zero sensitive isolates

Table 5: Antimicrobial susceptibility patterns for *Streptococcus* and *Enterococcus* species

Bacterial isolates	N	AMP	PEN	VA	LINE	FOSF	GM	TET	CIP	LEV	GATI
<i>E. faecalis</i>	7	7	7	7	7	7	6	2	4	4	4
<i>E. gallinarum</i>	2	0	0	2	2	1	0	0	0	0	0
<i>E. faecium</i>	1	1	1	1	1	1	1	0	0	1	1
<i>Streptococcus</i> <i>sp.</i>	3	1	1	2	3	2	2	1	2	2	2
Total N (%)	13(100)	9(69.2)	9(69.2)	12(92.3)	13(100)	11(84.6)	9(69.2)	3(23.1)	6(46.2)	7(53.8)	7(53.8)

Notes: AMP, ampicillin; PEN, penicillin; VA, vancomycin; LINE, linezolid; FOSF, fosfomycin; GM, gentamicin; TET, tetracycline; LEV, levofloxacin; CIP, ciprofloxacin; GATI, gatifloxacin; N, number; (0), zero sensitive isolates